文献速递心律失常

连续监测评估冷冻球囊与射频消融治疗房颤的随机临床试验

Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial.
PubMed 文献 · Circulation · 2019-10-21

该多中心随机单盲试验将346例药物难治性阵发性房颤患者分配至压力感知射频消融组、4分钟冷冻球囊组或2分钟冷冻球囊组,所有患者植入循环记录仪随访12个月。三组1年无房性心动过速复发率分别为53.9%、52.2%和51.7%(P=0.87),无差异;房颤负荷中位数降低均超过98%。

要点

  • 压力感知射频与两种冷冻球囊方案1年无复发率无显著差异(P=0.87)。
  • 连续监测下三组房颤负荷中位数降低均超过98%,组间无差异。
  • 射频组手术时间更长但透视时间更短(P<0.001)。

核心结论

  • 压力感知射频消融与4分钟或2分钟冷冻球囊消融在1年疗效上无差异,连续监测下无复发率约53%,但房颤负荷降低超过98%。

研究设计与样本

  • 多中心、随机、单盲试验纳入346例药物难治性阵发性房颤患者,随机分至压力感知射频消融组(n=115)、4分钟冷冻球囊组(n=115)或2分钟冷冻球囊组(n=116),随访12个月,所有患者植入循环记录仪。

主要发现

  • 1年无房性心动过速(房颤、房扑或房速)复发率在射频组、冷冻4分钟组和冷冻2分钟组分别为53.9%、52.2%和51.7%(P=0.87)。
  • 1年无症状性房性心动过速复发率分别为79.1%、78.2%和73.3%(P=0.26)。
  • 房颤负荷较消融前中位数降低分别为99.3%(四分位距67.8%-100.0%)、99.9%(65.3%-100.0%)和98.4%(56.2%-100.0%)(P=0.36)。
  • 严重不良事件发生率分别为2.6%(3例)、5.3%(6例)和6.0%(7例),组间无显著差异(P=0.24)。
  • 射频组手术时间显著更长但透视暴露时间显著更短(P<0.001 vs 冷冻球囊组)。

临床怎么用

  • 对于药物难治性阵发性房颤,压力感知射频消融与4分钟或2分钟冷冻球囊消融均可作为选择,1年疗效无显著差异。
  • 连续监测显示三种消融方式均能大幅降低房颤负荷,但1年无复发率仅约53%,需告知患者复发可能。
  • 选择消融方式时可结合手术时间和透视暴露时间等操作特征进行个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced generation ablation technologies have been developed to achieve more effective pulmonary vein isolation (PVI) and minimize arrhythmia recurrence after atrial fibrillation (AF) ablation. METHODS: We randomly assigned 346 patients with drug-refractory paroxysmal AF to contact force-guided radiofrequency ablation (CF-RF; n=115), 4-minute cryoballoon ablation (Cryo-4; n=115), or 2-minute cryoballoon ablation (Cryo-2; n=116). Follow-up was 12 months. The primary outcome was time to first documented recurrence of symptomatic or asymptomatic atrial tachyarrhythmia (AF, atrial flutter, or atrial tachycardia) between days 91 and 365 after ablation or a repeat ablation procedure at any time. Secondary end points included freedom from symptomatic arrhythmia and AF burden. All patients received an implantable loop recorder. RESULTS: One-year freedom from atrial tachyarrhythmia defined by continuous rhythm monitoring was 53.9%, 52.2%, and 51.7% with CF-RF, Cryo-4, and Cryo-2, respectively (P=0.87). One-year freedom from symptomatic atrial tachyarrhythmia defined by continuous rhythm monitoring was 79.1%, 78.2%, and 73.3% with CF-RF, Cryo-4, and Cryo-2, respectively (P=0.26). Compared with the monitoring period before ablation, AF burden was reduced by a median of 99.3% (interquartile range, 67.8%-100.0%) with CF-RF, 99.9% (interquartile range, 65.3%-100.0%) with Cryo-4, and 98.4% (interquartile range, 56.2%-100.0%) with Cryo-2 (P=0.36). Serious adverse events occurred in 3 patients (2.6%) in the CF-RF group, 6 patients (5.3%) in the Cryo-4 group, and 7 patients (6.0%) in the Cryo-2 group, with no significant difference between groups (P=0.24). The CF-RF group had a significantly longer procedure duration but significantly shorter fluoroscopy exposure (P<0.001 vs cryoballoon groups). CONCLUSIONS: In this multicenter, randomized, single-blinded trial, CF-RF and 2 different regimens of cryoballoon ablation resulted in no difference in 1-year efficacy, which was 53% by time to first recurrence but >98% burden reduction as assessed by continuous cardiac rhythm monitoring. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01913522.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial. Circulation. 2019. PMID: 31630538. doi:10.1161/CIRCULATIONAHA.119.042622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。